These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 16187646)
1. The drug add-on component--have all provider types seen budget neutrality? Mentz K Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646 [No Abstract] [Full Text] [Related]
2. Conditions for coverage fail to relieve administrative burden. Wish D Nephrol News Issues; 2005 Sep; 19(10):46-7, 51. PubMed ID: 16187648 [No Abstract] [Full Text] [Related]
3. Futuristic plans for ESRD--a new bundled payment system. Michael M Nephrol News Issues; 2005 Sep; 19(10):52, 54. PubMed ID: 16187649 [No Abstract] [Full Text] [Related]
4. The 2011 ESRD prospective payment system: welcome to the bundle. Weiner DE Am J Kidney Dis; 2011 Apr; 57(4):539-41. PubMed ID: 21333431 [No Abstract] [Full Text] [Related]
5. The 2011 ESRD prospective payment system: an uncontrolled experiment. Winkelmayer WC; Chertow GM Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428 [No Abstract] [Full Text] [Related]
6. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization. Bhat P; Bhat JG Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132 [No Abstract] [Full Text] [Related]
7. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization. Nissenson AR; Mayne TJ; Krishnan M Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425 [No Abstract] [Full Text] [Related]
8. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization. Lacson E; Hakim RM Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423 [No Abstract] [Full Text] [Related]
9. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
10. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization. Johnson DS; Meyer KB; Johnson HK Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427 [No Abstract] [Full Text] [Related]
11. Who should be paying for vitamin D analogues--Medicare or the patients? Grotegut J Nephrol Nurs J; 2006; 33(3):345-6. PubMed ID: 16912996 [No Abstract] [Full Text] [Related]
13. Who should be paying for vitamin D analogues--Medicare or the patients? Hall G Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205 [No Abstract] [Full Text] [Related]
15. How dialysis is paid for: what the dialysis medical director should know, and why. Deoreo PB Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259 [TBL] [Abstract][Full Text] [Related]
16. Adapting to changes in Medicare cost report requirements. Rossi T Nephrol News Issues; 2005 Sep; 19(10):36-9. PubMed ID: 16187645 [No Abstract] [Full Text] [Related]
17. Case-mix adjusted composite rate--did Medicare get it right? Messana A Nephrol News Issues; 2005 Sep; 19(10):44. PubMed ID: 16187647 [No Abstract] [Full Text] [Related]
18. The cost of clinical dialysis--a historical perspective. Attrill E; Johnson HK Semin Nephrol; 2000 Nov; 20(6):523-5. PubMed ID: 11111853 [No Abstract] [Full Text] [Related]
20. Is it time for Medicare to provide reimbursement for daily hemodialysis? Newmann JM Nephrol News Issues; 2001 Apr; 15(5):57-9. PubMed ID: 12108965 [No Abstract] [Full Text] [Related] [Next] [New Search]